US 12,447,173 B2
Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement C5
Seiji Takemoto, Nagoya (JP); Shuntaro Arase, Mizuho (JP); and Yuta Suzuki, Tsukuba (JP)
Assigned to Eisai R&D Management Co., Ltd., Tokyo (JP)
Appl. No. 17/768,283
Filed by Eisai R&D Management Co., Ltd., Tokyo (JP)
PCT Filed Dec. 24, 2020, PCT No. PCT/JP2020/048441
§ 371(c)(1), (2) Date Apr. 12, 2022,
PCT Pub. No. WO2021/132462, PCT Pub. Date Jul. 1, 2021.
Claims priority of application No. 2019-236918 (JP), filed on Dec. 26, 2019.
Prior Publication US 2024/0050462 A1, Feb. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/02 (2006.01); A61K 9/107 (2006.01); A61K 9/1272 (2025.01); A61K 31/713 (2006.01); A61P 13/02 (2006.01)
CPC A61K 31/713 (2013.01) [A61K 9/107 (2013.01); A61K 9/1272 (2013.01); A61P 13/02 (2018.01)] 20 Claims
 
1. A pharmaceutical composition comprising:
a lipid complex,
wherein the lipid complex comprises a double-stranded ribonucleic acid comprising a sense strand consisting of a nucleotide sequence set forth in SEQ ID NO: 145 and an antisense strand consisting of a nucleotide sequence set forth in SEQ ID NO: 146, and
a pH of a solution of the lipid complex is 5.0 or less or 7.5 or more.